REALATED ARTICLES

Click on a word or phrase in our Tag Cloud and see all related articles listed below.

Current tag:

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Prof. Andreas Busch January 2011. An unmasked account of decisions about investing into cancer stem cell research and the fate of regenerative medicine projects in Japan. Dr Busch summarises results and evaluates technology platforms like novel antibodies and wnt mechanisms. He voices his expectations from current key drug development partnerships, in particular with Oncomed and Micromet. Will these include companion diagnostics? To what extent does Bayer retain respective intellectual property rights? A comment on personalised medicine and cancer stem cells research pursued by Merck KGaA and others. What are prospects for classic oncology drugs?

Horizon Discovery: Mitigating risks and developing the U.S. business

Tasks ahead for Eric Rhodes, the new CTO

Roche Ethiopia: Build-up of an emerging market

Systems Biology: In search of good questions

Prof Walter Kolch on the approach taken by Systems Biology Ireland

B2Bioworld Stem Cell Insights Collection 2010:

Issues and Evaluation from Pharma Leaders

Dr Patrick Vallance, GSK:

Stem Cell Research Now and in the Future

No Mercy with Violators of Corporate Compliance

Dr Rüdiger Scheitza, Member of the Board Bayer CropScience, and Labour Director

If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

Drug Testing with Embryonic Stem Cells

– Towards Standards For Assays

(C) David C Hay 2009 As stem cell derived models of human liver biology move closer to diagnostic implementation there is an imperative for model standardization. Fresh experimental data is provided.

Reference
Hay DC (2009): Drug Testing with Embryonic Stem Cells – Towards Standards For Assays. published online September 12, B2Bioworld.com.

If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

Stem Cell Insights Collection 2010

Issues and Evaluation from Pharma Leaders

How does the pharma industry view application of stem cell technologies? Where are R&D efforts needed, and where does academic research not fulfill expectations? What is the role of suppliers in the field?

Read fresh answers from the leaders, provided exclusively to readers of B2Bioworld. Published only here, and all in one.

(C) Boehringer Ingelheim (C) Wolf G Kroner 2009 (C) Hoffmann-La Roche 2009

We are obliged to more and more move away from animal models
- Prof. Andreas Barner, Boehringer Ingelheim

Preparing for Another Level of Innovation
- Dr Mark Fishman, Novartis

Clear away complete confusion of terms
- Dr Bernhard Kirschbaum, Merck Serono

Stem Cells: a discovery tool and a potential therapeutic modality
- Dr Jonathan Knowles, Hoffmann-La Roche

It really started last year…
- Dr Ruth McKernan, Pfizer Regenerative Medicine

Stem Cells and Vaccines Production
- Dr Majid Mehtali, Vivalis

Doing our business a little bit differently than the others in the industry
- Dr Mads Krogsgaard, Novo Nordisk

Triggering Regenerative Functions with Transplanted Cells and Small Molecules
- Dr Kurt Stoeckli, Biological Sciences/Discovery Sanofi-Aventis

Stem Cell Research in GlaxoSmithKline and Beyond
- Dr Patrick Vallance, GlaxoSmithKline Drug Discovery

Stem Cells – Failings and Deliveries
- Hugh Ilyine, Consultant & Guest Editor

Patenting Stem Cells
- Dr. Sebastian Tegethoff, 24IP

Drug Testing with Embryonic Stem Cells – Towards Standards For Assays
– Dr David C Hay, University of Edinburgh, MRC Centre for Regenerative Medicine

L’Oréal avance dans les cellules souches
- Report by Hélène Guyot (with summary in English)

Buy the Entire Collection of Articles on Stem Cells here

If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

Pfizer Regenerative Medicine: “It really started last year…”

Ruth McKernan (c) Pfizer Inc. Pfizer is rapidly expanding work on stem cell applications. A first hand account by Dr Ruth McKernan, the global CSO of Pfizer’s activities in the field, an evaluation of toxicity screening with embryonic stem cells and needs to move forward.

If you would like to read more, please proceed to the download section.

Important: After pressing "Buy this article (PayPal)" below you will be taken to the PaypPal checkout page. There you must press the orange "Return To BioBusinessMedia" button in order to download your article.
In buying this article you agree with our Terms & Conditions which you can consult here.

xCELLigence System for Cell Analysis

xCelligence RTCA DP The extent to which protein targets are modulated by drugs or small molecule compounds depends on a number of factors, including the expression levels of the target, the effective concentration of the compound, and the time needed for the compound to perturb the target. One of the limitations of current multidimensional phenotypic profiling approaches is that typically a single time point is chosen to assess the effect of compounds. The conclusion, regarding the compounds´ mechanism of action, is based on the time point at which the samples are processed.

To address these restrictions, researchers Abassi et al. (1) have devised a live cell morphological profiling approach for dynamic monitoring of the effect of small molecule compounds that was based on impedance measurement of cells with the xCELLigence RTCA System of Roche Applied Science (SIX: RO, ROG; OTCQX: RHHBY). The approach was tested by screening a library containing FDA approved drugs, experimental compounds, and natural compounds. Compounds with similar activity produced similar impedance-based Time-dependent Cell Response Profiles (TCRPs). The compounds were clustered then based on TCRP similarity.

The researchers identified novel mechanisms for existing drugs, confirmed previously reported calcium modulating activity for COX-2 inhibitor celecoxib, and discovered an additional mechanism for the experimental compound monastrol. They also recognized and characterized a new antimitotic agent. This approach will also help to detect the off target effect of a given compound.

The TCRP technique described by Abassi et al. can overcome the limitations of current approaches, because the profile generated is time dependent. In combination with measurement of cell number, morphology, and adhesion, the TCR technique allows greater expansion of the ‘‘biological space’’ at which compounds are screened. It provides ample opportunity to detect and identify biological activity associated with small molecules.

In conclusion, these findings indicate that the time-dependant resolution, provided by the TCRP approach, can be used in conjunction with phenotypic profiling approaches to obtain additional data associated with small molecule compounds. TCRP approach provides predictive mechanistic information for small molecule compounds.

The non-invasive and label-free xCELLigence analysis method, originally invented by ACEA Biosciences in San Diego, USA is based on measuring the impedance of cells. The technique utilizes an electronic readout of impedance to non-invasively quantify cellular status in real-time. Cells are seeded in E-Plate microtiter plates, which are integrated with microelectronic sensor arrays. The interaction of cells with the microelectrode surface generates a cell-electrode impedance response, which not only indicates cell viability but also correlates with the number of the cells seeded in the well. In conjunction with its user-friendly data collection and analysis capabilities, the xCELLigence System makes a unique platform for continuous, real-time cell-based assays and provides a huge opportunity for cellular and molecular biology.

For more information on the technology, please visit www.roche-applied-science.com.

Literature:

(1) Abassi YA et al.: Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 2009; 16:712-723.

More information: www.xCELLigence.roche.com.

All trademarks used or mentioned in this release are protected by law.XCELLIGENCE is a trademark of Roche.E-PLATE and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US.

___________________________________________________________________________________________________________________________________

Disclaimer: You agree that B2Bioworld is not responsible and will not be held liable for any third party content on its sites or any third-party content, products or services available on other web sites accessed through links from B2Bioworld sites. Links to third-party sites are for your convenience only, and their inclusion on B2Bioworld's sites does not imply any endorsement, guarantee, warranty or representation by B2Bioworld.

REALATED ARTICLES

Bayer AG: New Stakes in Stem Cells

Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Related Articles

Horizon Discovery: Mitigating risks and developing the U.S. business

Roche Ethiopia: Build-up of an emerging market

Systems Biology: In search of good questions

B2Bioworld Stem Cell Insights Collection 2010:

Stem Cell Research Now and in the Future

No Mercy with Violators of Corporate Compliance

Drug Testing with Embryonic Stem Cells

– Towards Standards For Assays

Stem Cell Insights Collection 2010

Issues and Evaluation from Pharma Leaders

Pfizer Regenerative Medicine: “It really started last year…”

xCELLigence System for Cell Analysis

Top 10 Tags

All Tags (2094)

Lesezeichen / Weitersagen